Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-05-08

AUTHORS

Yutaka Yamamoto, Marco A De Velasco, Yurie Kura, Masahiro Nozawa, Yuji Hatanaka, Takashi Oki, Takayuki Ozeki, Nobutaka Shimizu, Takafumi Minami, Kazuhiro Yoshimura, Kazuhiro Yoshikawa, Kazuto Nishio, Hirotsugu Uemura

ABSTRACT

BACKGROUND: Despite recent advances in the treatment for advanced prostate cancer, outcomes remain poor. This lack of efficacy has prompted the development of alternative treatment strategies. In the present study we investigate the effects of the multikinase inhibitor sorafenib in a genetically engineered mouse model of prostate cancer and explore the rational combination with the mTOR inhibitor everolimus. METHODS: Conditional prostate specific PTEN-deficient knockout mice were utilized to determine the pharmacodynamic and chemopreventive effects of sorafenib. This mouse model was also used to examine the therapeutic efficacy of sorafenib alone or in combination with everolimus. Preclinical efficacy was assessed by comparing the reduction of tumor burden, proliferation, angiogenesis and the induction of apoptosis. Molecular responses were assessed by immunohistochemical, TUNEL and western blot assays. RESULTS: Pharmacodynamic analysis revealed that a single dose of sorafenib decreased activation of the PI3K/AKT/mTOR signaling axis at doses of 30-60 mg/kg, but activated JAK/STAT3 signaling. Levels of cleaved casapase-3 increased in a dose dependent manner. Chemoprevention studies showed that chronic sorafenib administration was capable of inhibiting tumor progression through the reduction of cancer cell proliferation, angiogenesis and the induction of apoptosis. In intervention models of established castration-naïve and castration-resistant prostate cancer, treatment with sorafenib provided modest but statistically insignificant reduction in tumor burden. However, sorafenib significantly inhibited cancer cell proliferation and MVD but had minimal effects on the induction of apoptosis. Interestingly, the administration of sorafenib increased the expression levels of the androgen receptor, p-GSK3β and p-ERK1/2 in castration-resistant prostate cancers. In both intervention models, combination therapy demonstrated a clear tendency of enhanced antitumor effects over monotherapy. Notably, the treatment combination of sorafenib and everolimus overcame therapeutic escape from single agent therapy in castration-resistant prostate cancers. CONCLUSIONS: In summary, we provide insights into the molecular responses of sorafenib therapy in a clinically relevant model of prostate cancer and present preclinical evidence for the development of targeted treatment strategies based on the use of multikinase inhibitors in combination with mTOR inhibitors for the treatment of advanced prostate cancer. More... »

PAGES

150

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12967-015-0509-x

DOI

http://dx.doi.org/10.1186/s12967-015-0509-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1015294223

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25953027


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Models, Animal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Everolimus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Engineering", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Homozygote", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunohistochemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "In Situ Nick-End Labeling", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice, Knockout", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms, Experimental", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neovascularization, Pathologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Niacinamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "PTEN Phosphohydrolase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sorafenib", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Yutaka", 
        "id": "sg:person.0745422532.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745422532.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Genome Biology, Kinki University Faculty of Medicine, Osaka-Sayama, 589-8511 Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan", 
            "Department of Genome Biology, Kinki University Faculty of Medicine, Osaka-Sayama, 589-8511 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Velasco", 
        "givenName": "Marco A", 
        "id": "sg:person.01271461543.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271461543.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kura", 
        "givenName": "Yurie", 
        "id": "sg:person.01341453576.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341453576.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nozawa", 
        "givenName": "Masahiro", 
        "id": "sg:person.01012426117.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012426117.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hatanaka", 
        "givenName": "Yuji", 
        "id": "sg:person.011676601423.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011676601423.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Oki", 
        "givenName": "Takashi", 
        "id": "sg:person.01273762025.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273762025.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ozeki", 
        "givenName": "Takayuki", 
        "id": "sg:person.01263540121.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263540121.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shimizu", 
        "givenName": "Nobutaka", 
        "id": "sg:person.01321716550.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01321716550.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Minami", 
        "givenName": "Takafumi", 
        "id": "sg:person.01013535732.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013535732.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoshimura", 
        "givenName": "Kazuhiro", 
        "id": "sg:person.0713044310.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713044310.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Promoting Center for Clinical Research, Aichi Medical University, School of Medicine, Nagakute, Aichi 480-1195 Japan", 
          "id": "http://www.grid.ac/institutes/grid.411234.1", 
          "name": [
            "Promoting Center for Clinical Research, Aichi Medical University, School of Medicine, Nagakute, Aichi 480-1195 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoshikawa", 
        "givenName": "Kazuhiro", 
        "id": "sg:person.0766017060.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766017060.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Genome Biology, Kinki University Faculty of Medicine, Osaka-Sayama, 589-8511 Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Genome Biology, Kinki University Faculty of Medicine, Osaka-Sayama, 589-8511 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishio", 
        "givenName": "Kazuto", 
        "id": "sg:person.01062765675.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062765675.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan", 
          "id": "http://www.grid.ac/institutes/grid.258622.9", 
          "name": [
            "Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uemura", 
        "givenName": "Hirotsugu", 
        "id": "sg:person.01051464055.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051464055.75"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nm.2537", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031152422", 
          "https://doi.org/10.1038/nm.2537"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-013-2117-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041735879", 
          "https://doi.org/10.1007/s00280-013-2117-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc3818", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014076105", 
          "https://doi.org/10.1038/nrc3818"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nmeth.2089", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035817137", 
          "https://doi.org/10.1038/nmeth.2089"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-05-08", 
    "datePublishedReg": "2015-05-08", 
    "description": "BACKGROUND: Despite recent advances in the treatment for advanced prostate cancer, outcomes remain poor. This lack of efficacy has prompted the development of alternative treatment strategies. In the present study we investigate the effects of the multikinase inhibitor sorafenib in a genetically engineered mouse model of prostate cancer and explore the rational combination with the mTOR inhibitor everolimus.\nMETHODS: Conditional prostate specific PTEN-deficient knockout mice were utilized to determine the pharmacodynamic and chemopreventive effects of sorafenib. This mouse model was also used to examine the therapeutic efficacy of sorafenib alone or in combination with everolimus. Preclinical efficacy was assessed by comparing the reduction of tumor burden, proliferation, angiogenesis and the induction of apoptosis. Molecular responses were assessed by immunohistochemical, TUNEL and western blot assays.\nRESULTS: Pharmacodynamic analysis revealed that a single dose of sorafenib decreased activation of the PI3K/AKT/mTOR signaling axis at doses of 30-60 mg/kg, but activated JAK/STAT3 signaling. Levels of cleaved casapase-3 increased in a dose dependent manner. Chemoprevention studies showed that chronic sorafenib administration was capable of inhibiting tumor progression through the reduction of cancer cell proliferation, angiogenesis and the induction of apoptosis. In intervention models of established castration-na\u00efve and castration-resistant prostate cancer, treatment with sorafenib provided modest but statistically insignificant reduction in tumor burden. However, sorafenib significantly inhibited cancer cell proliferation and MVD but had minimal effects on the induction of apoptosis. Interestingly, the administration of sorafenib increased the expression levels of the androgen receptor, p-GSK3\u03b2 and p-ERK1/2 in castration-resistant prostate cancers. In both intervention models, combination therapy demonstrated a clear tendency of enhanced antitumor effects over monotherapy. Notably, the treatment combination of sorafenib and everolimus overcame therapeutic escape from single agent therapy in castration-resistant prostate cancers.\nCONCLUSIONS: In summary, we provide insights into the molecular responses of sorafenib therapy in a clinically relevant model of prostate cancer and present preclinical evidence for the development of targeted treatment strategies based on the use of multikinase inhibitors in combination with mTOR inhibitors for the treatment of advanced prostate cancer.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12967-015-0509-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.6046100", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6147533", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1032886", 
        "issn": [
          "1479-5876"
        ], 
        "name": "Journal of Translational Medicine", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "keywords": [
      "castration-resistant prostate cancer", 
      "advanced prostate cancer", 
      "prostate cancer", 
      "cancer cell proliferation", 
      "mouse model", 
      "induction of apoptosis", 
      "sorafenib therapy", 
      "tumor burden", 
      "treatment strategies", 
      "single-agent therapy", 
      "PI3K/Akt/mTOR", 
      "mTOR inhibitor everolimus", 
      "lack of efficacy", 
      "cell proliferation", 
      "administration of sorafenib", 
      "alternative treatment strategies", 
      "preclinical mouse models", 
      "multikinase inhibitor sorafenib", 
      "present preclinical evidence", 
      "enhanced antitumor effect", 
      "Akt/mTOR", 
      "dose-dependent manner", 
      "Western blot assays", 
      "JAK/STAT3", 
      "sorafenib administration", 
      "agent therapy", 
      "preclinical evidence", 
      "chemoprevention studies", 
      "inhibitor everolimus", 
      "single dose", 
      "combination therapy", 
      "pharmacodynamic analysis", 
      "preclinical efficacy", 
      "androgen receptor", 
      "multikinase inhibitor", 
      "chemopreventive effects", 
      "molecular response", 
      "intervention model", 
      "inhibitor sorafenib", 
      "knockout mice", 
      "antitumor effects", 
      "mTOR inhibitors", 
      "therapeutic escape", 
      "sorafenib", 
      "therapeutic efficacy", 
      "tumor progression", 
      "cancer", 
      "therapy", 
      "everolimus", 
      "vivo response", 
      "blot assays", 
      "casapase-3", 
      "efficacy", 
      "expression levels", 
      "dependent manner", 
      "insignificant reduction", 
      "treatment", 
      "administration", 
      "apoptosis", 
      "proliferation", 
      "present study", 
      "angiogenesis", 
      "induction", 
      "rational combination", 
      "relevant model", 
      "burden", 
      "minimal effect", 
      "inhibitors", 
      "monotherapy", 
      "response", 
      "mice", 
      "dose", 
      "doses", 
      "progression", 
      "TUNEL", 
      "receptors", 
      "mTOR", 
      "ERK1/2", 
      "outcomes", 
      "GSK3\u03b2", 
      "effect", 
      "STAT3", 
      "levels", 
      "treatment combinations", 
      "reduction", 
      "MVD", 
      "recent advances", 
      "study", 
      "activation", 
      "combination", 
      "assays", 
      "clear tendency", 
      "evidence", 
      "development", 
      "strategies", 
      "evaluation", 
      "summary", 
      "lack", 
      "manner", 
      "escape", 
      "use", 
      "advances", 
      "model", 
      "axis", 
      "tendency", 
      "analysis", 
      "insights", 
      "Conditional prostate specific PTEN-deficient knockout mice", 
      "prostate specific PTEN-deficient knockout mice", 
      "specific PTEN-deficient knockout mice", 
      "PTEN-deficient knockout mice", 
      "chronic sorafenib administration"
    ], 
    "name": "Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer", 
    "pagination": "150", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1015294223"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12967-015-0509-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25953027"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12967-015-0509-x", 
      "https://app.dimensions.ai/details/publication/pub.1015294223"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:39", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_683.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12967-015-0509-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12967-015-0509-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12967-015-0509-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12967-015-0509-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12967-015-0509-x'


 

This table displays all metadata directly associated to this object as RDF triples.

366 TRIPLES      22 PREDICATES      163 URIs      151 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12967-015-0509-x schema:about N01ce8f3bbbdd48cdb196a6c9591f0d69
2 N06f88e0b13be43a4bedd4980728d1e5d
3 N16df7e60c6684758b2d14f84a7d2dd8b
4 N1d78259c153a41e79b24a7237423bcdd
5 N2c0425d1fd5644ffb4ab91164a9b0520
6 N34b31fcde0484f6a96ea42b426af6e73
7 N3b850aff105f45f6b21362ad6ef0c390
8 N486e6e0fee344960bed40419ca91a59e
9 N572195817d6d4898b36cfdab0fb71db9
10 N5806bc274a364e84b53829c38d3fa684
11 N608b8f26c2924a648a4e429be7f4b602
12 N630e4898f21e4339b4e4036677d033d1
13 Nd6ce8bad1fb244d09546ae98d2444673
14 Ndbacf76e594a4ee99a704773b19d35c7
15 Ndc7f12021fdd42f4a05e8a1240e7922f
16 Ne1d361fa30034f1997749a7281303b4b
17 Ne569786bb7fc40308f45722c7ee1b71a
18 Ne5edf2bb889b4f9fb8a7d16db642deec
19 Ne859a46ef283412992ab8dca76a70cb3
20 Nee9cfb28707747728076a38de782703d
21 Nf22a843fa9ca459f9559cd66e62c0f06
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N4d50c47919da40c0b724aa45cc219fc2
25 schema:citation sg:pub.10.1007/s00280-013-2117-x
26 sg:pub.10.1038/nm.2537
27 sg:pub.10.1038/nmeth.2089
28 sg:pub.10.1038/nrc3818
29 schema:datePublished 2015-05-08
30 schema:datePublishedReg 2015-05-08
31 schema:description BACKGROUND: Despite recent advances in the treatment for advanced prostate cancer, outcomes remain poor. This lack of efficacy has prompted the development of alternative treatment strategies. In the present study we investigate the effects of the multikinase inhibitor sorafenib in a genetically engineered mouse model of prostate cancer and explore the rational combination with the mTOR inhibitor everolimus. METHODS: Conditional prostate specific PTEN-deficient knockout mice were utilized to determine the pharmacodynamic and chemopreventive effects of sorafenib. This mouse model was also used to examine the therapeutic efficacy of sorafenib alone or in combination with everolimus. Preclinical efficacy was assessed by comparing the reduction of tumor burden, proliferation, angiogenesis and the induction of apoptosis. Molecular responses were assessed by immunohistochemical, TUNEL and western blot assays. RESULTS: Pharmacodynamic analysis revealed that a single dose of sorafenib decreased activation of the PI3K/AKT/mTOR signaling axis at doses of 30-60 mg/kg, but activated JAK/STAT3 signaling. Levels of cleaved casapase-3 increased in a dose dependent manner. Chemoprevention studies showed that chronic sorafenib administration was capable of inhibiting tumor progression through the reduction of cancer cell proliferation, angiogenesis and the induction of apoptosis. In intervention models of established castration-naïve and castration-resistant prostate cancer, treatment with sorafenib provided modest but statistically insignificant reduction in tumor burden. However, sorafenib significantly inhibited cancer cell proliferation and MVD but had minimal effects on the induction of apoptosis. Interestingly, the administration of sorafenib increased the expression levels of the androgen receptor, p-GSK3β and p-ERK1/2 in castration-resistant prostate cancers. In both intervention models, combination therapy demonstrated a clear tendency of enhanced antitumor effects over monotherapy. Notably, the treatment combination of sorafenib and everolimus overcame therapeutic escape from single agent therapy in castration-resistant prostate cancers. CONCLUSIONS: In summary, we provide insights into the molecular responses of sorafenib therapy in a clinically relevant model of prostate cancer and present preclinical evidence for the development of targeted treatment strategies based on the use of multikinase inhibitors in combination with mTOR inhibitors for the treatment of advanced prostate cancer.
32 schema:genre article
33 schema:inLanguage en
34 schema:isAccessibleForFree true
35 schema:isPartOf N2ea802ebe8fb4249bd28f5693f8ea7d8
36 N7a453461dd1a40a1a41de023d81233ba
37 sg:journal.1032886
38 schema:keywords Akt/mTOR
39 Conditional prostate specific PTEN-deficient knockout mice
40 ERK1/2
41 GSK3β
42 JAK/STAT3
43 MVD
44 PI3K/Akt/mTOR
45 PTEN-deficient knockout mice
46 STAT3
47 TUNEL
48 Western blot assays
49 activation
50 administration
51 administration of sorafenib
52 advanced prostate cancer
53 advances
54 agent therapy
55 alternative treatment strategies
56 analysis
57 androgen receptor
58 angiogenesis
59 antitumor effects
60 apoptosis
61 assays
62 axis
63 blot assays
64 burden
65 cancer
66 cancer cell proliferation
67 casapase-3
68 castration-resistant prostate cancer
69 cell proliferation
70 chemoprevention studies
71 chemopreventive effects
72 chronic sorafenib administration
73 clear tendency
74 combination
75 combination therapy
76 dependent manner
77 development
78 dose
79 dose-dependent manner
80 doses
81 effect
82 efficacy
83 enhanced antitumor effect
84 escape
85 evaluation
86 everolimus
87 evidence
88 expression levels
89 induction
90 induction of apoptosis
91 inhibitor everolimus
92 inhibitor sorafenib
93 inhibitors
94 insights
95 insignificant reduction
96 intervention model
97 knockout mice
98 lack
99 lack of efficacy
100 levels
101 mTOR
102 mTOR inhibitor everolimus
103 mTOR inhibitors
104 manner
105 mice
106 minimal effect
107 model
108 molecular response
109 monotherapy
110 mouse model
111 multikinase inhibitor
112 multikinase inhibitor sorafenib
113 outcomes
114 pharmacodynamic analysis
115 preclinical efficacy
116 preclinical evidence
117 preclinical mouse models
118 present preclinical evidence
119 present study
120 progression
121 proliferation
122 prostate cancer
123 prostate specific PTEN-deficient knockout mice
124 rational combination
125 recent advances
126 receptors
127 reduction
128 relevant model
129 response
130 single dose
131 single-agent therapy
132 sorafenib
133 sorafenib administration
134 sorafenib therapy
135 specific PTEN-deficient knockout mice
136 strategies
137 study
138 summary
139 tendency
140 therapeutic efficacy
141 therapeutic escape
142 therapy
143 treatment
144 treatment combinations
145 treatment strategies
146 tumor burden
147 tumor progression
148 use
149 vivo response
150 schema:name Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer
151 schema:pagination 150
152 schema:productId N0255fd651f4148649458294a70f4361e
153 N6bd2b1422e2b4ac4a693ab52f5b9f97d
154 N921fd794959a49798b054c94a78a4e9f
155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015294223
156 https://doi.org/10.1186/s12967-015-0509-x
157 schema:sdDatePublished 2022-01-01T18:39
158 schema:sdLicense https://scigraph.springernature.com/explorer/license/
159 schema:sdPublisher N3f3af0e6ab454ff6a47abd6c206b1a1e
160 schema:url https://doi.org/10.1186/s12967-015-0509-x
161 sgo:license sg:explorer/license/
162 sgo:sdDataset articles
163 rdf:type schema:ScholarlyArticle
164 N01ce8f3bbbdd48cdb196a6c9591f0d69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Antineoplastic Combined Chemotherapy Protocols
166 rdf:type schema:DefinedTerm
167 N0255fd651f4148649458294a70f4361e schema:name dimensions_id
168 schema:value pub.1015294223
169 rdf:type schema:PropertyValue
170 N06f88e0b13be43a4bedd4980728d1e5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Disease Models, Animal
172 rdf:type schema:DefinedTerm
173 N0d9036f47737416dba2c079b88f02ba3 rdf:first sg:person.011676601423.42
174 rdf:rest Na9ca80609464468a8361dd2bb8bd1088
175 N16df7e60c6684758b2d14f84a7d2dd8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Apoptosis
177 rdf:type schema:DefinedTerm
178 N1d78259c153a41e79b24a7237423bcdd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Animals
180 rdf:type schema:DefinedTerm
181 N2c0425d1fd5644ffb4ab91164a9b0520 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name In Situ Nick-End Labeling
183 rdf:type schema:DefinedTerm
184 N2daa5be40f3845fe957d5d4640b05227 rdf:first sg:person.01051464055.75
185 rdf:rest rdf:nil
186 N2ea802ebe8fb4249bd28f5693f8ea7d8 schema:volumeNumber 13
187 rdf:type schema:PublicationVolume
188 N34b31fcde0484f6a96ea42b426af6e73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name PTEN Phosphohydrolase
190 rdf:type schema:DefinedTerm
191 N3b850aff105f45f6b21362ad6ef0c390 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Mice, Knockout
193 rdf:type schema:DefinedTerm
194 N3cf6be9d44e243d6b198b9b2a2fd9b2f rdf:first sg:person.01062765675.36
195 rdf:rest N2daa5be40f3845fe957d5d4640b05227
196 N3f3af0e6ab454ff6a47abd6c206b1a1e schema:name Springer Nature - SN SciGraph project
197 rdf:type schema:Organization
198 N448f029c2a7b4708b04391538332f738 rdf:first sg:person.01321716550.53
199 rdf:rest N91dc98fb4db34f95b4605fe14a05404a
200 N46484b2149464097aea96714a07c0665 rdf:first sg:person.01263540121.67
201 rdf:rest N448f029c2a7b4708b04391538332f738
202 N486e6e0fee344960bed40419ca91a59e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Sorafenib
204 rdf:type schema:DefinedTerm
205 N4d50c47919da40c0b724aa45cc219fc2 rdf:first sg:person.0745422532.92
206 rdf:rest N5ef7596143b945908ebf1da8404b3786
207 N572195817d6d4898b36cfdab0fb71db9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Homozygote
209 rdf:type schema:DefinedTerm
210 N5806bc274a364e84b53829c38d3fa684 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Neoplasms, Experimental
212 rdf:type schema:DefinedTerm
213 N5ef7596143b945908ebf1da8404b3786 rdf:first sg:person.01271461543.03
214 rdf:rest N6d827f4a1bd449c0af1e0a0eb5da4911
215 N608b8f26c2924a648a4e429be7f4b602 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name Genetic Engineering
217 rdf:type schema:DefinedTerm
218 N630e4898f21e4339b4e4036677d033d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Cell Proliferation
220 rdf:type schema:DefinedTerm
221 N6bd2b1422e2b4ac4a693ab52f5b9f97d schema:name pubmed_id
222 schema:value 25953027
223 rdf:type schema:PropertyValue
224 N6d827f4a1bd449c0af1e0a0eb5da4911 rdf:first sg:person.01341453576.33
225 rdf:rest Ne3bf9fee80864441a7c36819925891e9
226 N7a453461dd1a40a1a41de023d81233ba schema:issueNumber 1
227 rdf:type schema:PublicationIssue
228 N91dc98fb4db34f95b4605fe14a05404a rdf:first sg:person.01013535732.27
229 rdf:rest Nb69da4acb62d44e9b3de38c386a9ebbd
230 N921fd794959a49798b054c94a78a4e9f schema:name doi
231 schema:value 10.1186/s12967-015-0509-x
232 rdf:type schema:PropertyValue
233 Na9ca80609464468a8361dd2bb8bd1088 rdf:first sg:person.01273762025.26
234 rdf:rest N46484b2149464097aea96714a07c0665
235 Nb69da4acb62d44e9b3de38c386a9ebbd rdf:first sg:person.0713044310.72
236 rdf:rest Nf7a024a5d1c5430987c63e7fede78ade
237 Nd6ce8bad1fb244d09546ae98d2444673 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
238 schema:name Prostatic Neoplasms
239 rdf:type schema:DefinedTerm
240 Ndbacf76e594a4ee99a704773b19d35c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
241 schema:name Signal Transduction
242 rdf:type schema:DefinedTerm
243 Ndc7f12021fdd42f4a05e8a1240e7922f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
244 schema:name Everolimus
245 rdf:type schema:DefinedTerm
246 Ne1d361fa30034f1997749a7281303b4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
247 schema:name Phenylurea Compounds
248 rdf:type schema:DefinedTerm
249 Ne3bf9fee80864441a7c36819925891e9 rdf:first sg:person.01012426117.40
250 rdf:rest N0d9036f47737416dba2c079b88f02ba3
251 Ne569786bb7fc40308f45722c7ee1b71a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
252 schema:name Male
253 rdf:type schema:DefinedTerm
254 Ne5edf2bb889b4f9fb8a7d16db642deec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
255 schema:name Niacinamide
256 rdf:type schema:DefinedTerm
257 Ne859a46ef283412992ab8dca76a70cb3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
258 schema:name Immunohistochemistry
259 rdf:type schema:DefinedTerm
260 Nee9cfb28707747728076a38de782703d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
261 schema:name Neovascularization, Pathologic
262 rdf:type schema:DefinedTerm
263 Nf22a843fa9ca459f9559cd66e62c0f06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
264 schema:name Mice
265 rdf:type schema:DefinedTerm
266 Nf7a024a5d1c5430987c63e7fede78ade rdf:first sg:person.0766017060.02
267 rdf:rest N3cf6be9d44e243d6b198b9b2a2fd9b2f
268 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
269 schema:name Medical and Health Sciences
270 rdf:type schema:DefinedTerm
271 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
272 schema:name Oncology and Carcinogenesis
273 rdf:type schema:DefinedTerm
274 sg:grant.6046100 http://pending.schema.org/fundedItem sg:pub.10.1186/s12967-015-0509-x
275 rdf:type schema:MonetaryGrant
276 sg:grant.6147533 http://pending.schema.org/fundedItem sg:pub.10.1186/s12967-015-0509-x
277 rdf:type schema:MonetaryGrant
278 sg:journal.1032886 schema:issn 1479-5876
279 schema:name Journal of Translational Medicine
280 schema:publisher Springer Nature
281 rdf:type schema:Periodical
282 sg:person.01012426117.40 schema:affiliation grid-institutes:grid.258622.9
283 schema:familyName Nozawa
284 schema:givenName Masahiro
285 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012426117.40
286 rdf:type schema:Person
287 sg:person.01013535732.27 schema:affiliation grid-institutes:grid.258622.9
288 schema:familyName Minami
289 schema:givenName Takafumi
290 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013535732.27
291 rdf:type schema:Person
292 sg:person.01051464055.75 schema:affiliation grid-institutes:grid.258622.9
293 schema:familyName Uemura
294 schema:givenName Hirotsugu
295 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051464055.75
296 rdf:type schema:Person
297 sg:person.01062765675.36 schema:affiliation grid-institutes:grid.258622.9
298 schema:familyName Nishio
299 schema:givenName Kazuto
300 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062765675.36
301 rdf:type schema:Person
302 sg:person.011676601423.42 schema:affiliation grid-institutes:grid.258622.9
303 schema:familyName Hatanaka
304 schema:givenName Yuji
305 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011676601423.42
306 rdf:type schema:Person
307 sg:person.01263540121.67 schema:affiliation grid-institutes:grid.258622.9
308 schema:familyName Ozeki
309 schema:givenName Takayuki
310 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01263540121.67
311 rdf:type schema:Person
312 sg:person.01271461543.03 schema:affiliation grid-institutes:grid.258622.9
313 schema:familyName De Velasco
314 schema:givenName Marco A
315 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271461543.03
316 rdf:type schema:Person
317 sg:person.01273762025.26 schema:affiliation grid-institutes:grid.258622.9
318 schema:familyName Oki
319 schema:givenName Takashi
320 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273762025.26
321 rdf:type schema:Person
322 sg:person.01321716550.53 schema:affiliation grid-institutes:grid.258622.9
323 schema:familyName Shimizu
324 schema:givenName Nobutaka
325 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01321716550.53
326 rdf:type schema:Person
327 sg:person.01341453576.33 schema:affiliation grid-institutes:grid.258622.9
328 schema:familyName Kura
329 schema:givenName Yurie
330 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341453576.33
331 rdf:type schema:Person
332 sg:person.0713044310.72 schema:affiliation grid-institutes:grid.258622.9
333 schema:familyName Yoshimura
334 schema:givenName Kazuhiro
335 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0713044310.72
336 rdf:type schema:Person
337 sg:person.0745422532.92 schema:affiliation grid-institutes:grid.258622.9
338 schema:familyName Yamamoto
339 schema:givenName Yutaka
340 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745422532.92
341 rdf:type schema:Person
342 sg:person.0766017060.02 schema:affiliation grid-institutes:grid.411234.1
343 schema:familyName Yoshikawa
344 schema:givenName Kazuhiro
345 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766017060.02
346 rdf:type schema:Person
347 sg:pub.10.1007/s00280-013-2117-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041735879
348 https://doi.org/10.1007/s00280-013-2117-x
349 rdf:type schema:CreativeWork
350 sg:pub.10.1038/nm.2537 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031152422
351 https://doi.org/10.1038/nm.2537
352 rdf:type schema:CreativeWork
353 sg:pub.10.1038/nmeth.2089 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035817137
354 https://doi.org/10.1038/nmeth.2089
355 rdf:type schema:CreativeWork
356 sg:pub.10.1038/nrc3818 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014076105
357 https://doi.org/10.1038/nrc3818
358 rdf:type schema:CreativeWork
359 grid-institutes:grid.258622.9 schema:alternateName Department of Genome Biology, Kinki University Faculty of Medicine, Osaka-Sayama, 589-8511 Japan
360 Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan
361 schema:name Department of Genome Biology, Kinki University Faculty of Medicine, Osaka-Sayama, 589-8511 Japan
362 Department of Urology, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, 589-8511 Japan
363 rdf:type schema:Organization
364 grid-institutes:grid.411234.1 schema:alternateName Promoting Center for Clinical Research, Aichi Medical University, School of Medicine, Nagakute, Aichi 480-1195 Japan
365 schema:name Promoting Center for Clinical Research, Aichi Medical University, School of Medicine, Nagakute, Aichi 480-1195 Japan
366 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...